Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD Leqvio® - Inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT03705234 ORION-4 (CKJX839B12301) Hypercholesterolemia inc. Heterozygous Familial Hypercholesterolaemia (HeFH) Phase 3 ~15000 A composite of major adverse cardiovascular events, defined as: Coronary heart disease (CHD) death; Myocardial infarction; Fatal or non-fatal ischaemic stroke; or Urgent coronary revascularization procedure Arm 1: every 6 month treatment Inclisiran sodium 300mg (given by subcutaneous injection on the day of randomization, at 3 months and then every 6- months) for a planned median duration of about 5 years Arm 2: matching placebo (given by subcutaneous injection on the day of randomization, at 3 months and then every 6-months) for a planned median duration of about 5 years. Patient population with mean baseline LDL-C >= 100mg/dL Read-out Milesstone(s) 2026 Publication TBD 63 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation